BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioScrip (BIOS) Announces Secondary Public Offering of Common Stock


8/14/2013 10:01:25 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ELMSFORD, N.Y., Aug. 13, 2013 /PRNewswire/ -- BioScrip®, Inc. (NASDAQ: BIOS) ("BioScrip") announced today that it has commenced a registered underwritten public offering of 6,800,000 shares of its common stock, all of which will be offered by selling stockholders. The underwriter of this offering has been granted an option, exercisable within 30 days, to purchase up to an additional 1,020,000 shares of common stock from the selling stockholders on the same terms and conditions. BioScrip will not receive any of the proceeds from the initial sale of the shares of common stock or the sale of any additional shares pursuant to the option. The total number of shares of common stock outstanding will not change as a result of this offering.

(Logo: http://photos.prnewswire.com/prnh/20130117/NY44138LOGO )

Morgan Stanley & Co. LLC is acting as the sole underwriter of the offering.

A shelf registration statement, including a prospectus, with respect to the offering was previously filed by BioScrip with the Securities and Exchange Commission ("SEC") and became effective on April 4, 2013. A preliminary prospectus supplement relating to the offering has been filed with the SEC. The offering will be made only by means of a prospectus supplement and the accompanying base prospectus. When available, copies of the prospectus supplement and the accompanying prospectus relating to these securities may be obtained without charge from Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by calling (866) 718-1649 or (917) 606-8474 or by emailing prospectus@morganstanley.com. A copy of the prospectus supplement and the accompanying base prospectus may also be obtained without charge by visiting the SEC website at www.sec.gov.

This press release is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any security, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BioScrip

BioScrip, Inc. provides comprehensive infusion and home care solutions. By partnering with patients, physicians, healthcare payors, government agencies and pharmaceutical manufacturers, BioScrip is able to provide access to infusible medications and management solutions. BioScrip's goal is to optimize outcomes for chronic and other complex healthcare conditions and enhance the quality of patient life. BioScrip brings clinical competence in providing high-touch, comprehensive infusion and nursing services to patients in the most convenient ways possible. Through its customer services and treatments BioScrip aims to ensure the best possible therapy outcome.

Forward-Looking Statements

This press release includes statements that may constitute "forward-looking statements" conveying management's expectations as to the future based on current plans, estimates and projections. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historical or current facts. In some cases, forward-looking statements can be identified by words such as "may," "should," "could," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "predict," "potential," "continue" or comparable terms. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and, because such statements inherently involve risks and uncertainties, actual results may differ materially from those in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. BioScrip does not undertake any duty to update these forward-looking statements after the date hereof, even though BioScrip's situation may change in the future, except, with respect to the offering, as required by law. All of the forward-looking statements herein are qualified by these cautionary statements.

SOURCE BioScrip, Inc.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

BioScrip
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES